Clinical trial
A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents
NCT03205995 is registered in ClinicalTrials.gov with Omeros Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents
- Lead sponsor
- Omeros Corporation
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- May 2, 2018
- Completion date
- February 2, 2021
- Enrollment
- 6 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.